Learn effective methods for managing neuropathic pain through integrative approaches to alleviate symptoms and enhance overall wellness.

Abstract

In this educational post, I take you inside the real-world, evidence-based journey of managing severe, evolving neuropathic pain in an older adult whose symptoms began as postherpetic neuralgia and progressed into a complex, refractory state. I explain the physiological underpinnings of neuropathic pain, the rationale for adjuvant analgesics (antiepileptics and antidepressants), the mechanics and safety rules for opioid titration and opioid rotation, and how we diagnose and treat opioid-induced hyperalgesia. I also detail when and why we introduce methadone and progress to an intrathecal pain pump, including conversion principles and risk mitigation. Throughout, I show how our multidisciplinary model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, integrates chiropractic care, regenerative medicine (including PRP therapy), functional medicine, rehabilitation, and medical oversight. Our collaborative physician and Medical Director, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), brings more than 40 years of medical experience, ensuring safety and precision across complex decision points. This narrative merges bedside pragmatism with modern, peer-reviewed science, providing a clear, comprehensive path to addressing complex neuropathic pain while honoring patient goals and quality of life.

—

Our Integrative Clinic Model in El Paso: Medicine, Chiropractic, Functional Care, and Regenerative Therapies Working as One

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, our core principle is integrative, multidisciplinary care. We combine medical oversight with chiropractic, regenerative medicine (including PRP therapy), functional medicine, rehabilitation, and personal injury services to deliver seamless, patient-centered plans.

Central to our model is the collaboration with Dr. Maria Guadalupe Cardenas, MD—an internist with over four decades of experience—who serves as our Medical Director and Collaborative Physician. Dr. Cardenas provides primary medical diagnosis, prescription management, risk assessment (including renal/hepatic considerations, QTc, drug interactions), and overall medical direction. In parallel, I bring the structural and neuromodulatory lens of chiropractic care, the systems-level perspective of functional medicine, and regenerative interventions to address biomechanical drivers, metabolic stressors, localized inflammation, and tissue healing needs.

Our coordinated workflow includes:

• Medical Oversight (Dr. Cardenas): Diagnostic synthesis, imaging and labs, pharmacology, comorbidity management, safety guardrails, and hospital-to-home continuity.
• Chiropractic Care (Dr. Jimenez): Spinal and rib mechanics, soft tissue and myofascial therapies, sensorimotor neuromodulation, and posture-breathing integration.
• Regenerative Therapies (integrated team): Ultrasound-guided PRP and orthobiologic injections to target neuroinflammatory processes, support tissue repair around affected nerves and thoracic structures, reduce peripheral sensitization, and complement neuromodulatory effects.
• Functional Medicine: Nutrition, inflammation biology, gut-brain axis, precision supplementation, sleep, and stress optimization.
• Rehabilitation & Personal Injury Care: Individualized mobility restoration, graded exercise, ergonomics, and recovery planning.

This model is common in modern integrative and injury clinics because it aligns medical precision with whole-person and regenerative strategies, improving pain control and functional outcomes while minimizing risks.

—

Deconstructing a Complex Pain Journey: From “Electric Shocks” to Refractory Neuropathic Pain

Patient Context and Clinical Course

A 70-year-old woman presented with severe, constant, right-sided thoracic pain described as “a thousand stinging electric shocks,” classically neuropathic in the setting of postherpetic neuralgia following shingles. She developed a pleural effusion requiring thoracentesis. A procedural complication led to pneumothorax and chest tube placement, escalating acute pain atop the chronic neuropathic foundation. On exam, she had tenderness in a T4–T8 dermatomal distribution and allodynia—pain to light touch—strongly suggesting neuropathic mechanisms with peripheral and central sensitization.

Over days, the case evolved: the patient underwent additional pleural drainage procedures to manage complications; pain fluctuated amid changes to PCA and oral regimens; adjuvants were tested and rotated. Comprehensive evaluation confirmed a complex neuropathic pain syndrome with thoracic wall and nerve involvement. Functional impairment was significant, and goals of care centered on achieving meaningful pain reduction, improving mobility and nutrition, and enhancing overall quality of life.

—

Pain Assessment That Guides Strategy: PQRSTU and Functional Impact

I rely on structured frameworks like PQRSTU to prevent rushed or fragmented decisions:

• P – Precipitating/Palliating: Pain was continuous; prior gabapentin failed and caused leg edema. Learning from the side-effect history guides cautious dosing of pregabalin or alternative adjuvants.
• Q – Quality: “Stinging electric shocks” suggests hyperexcitability of peripheral/central pathways—neuropathic pain often resists opioids alone.
• R – Region/Radiation: T4–T8 dermatomal distribution and allodynia highlight segmental involvement at the thoracic spine/rib interface and dorsal horn sensitization.
• S – Severity and Goals: Reported 5–7/10 with a target of ~3/10. Setting realistic expectations avoids harmful escalation and anchors shared decision-making.
• T – Temporal: Constant pain with short-lived relief after PCA boluses indicates the need for basal coverage and long-acting strategies.
• U – “Impact on You”: Debilitating pain impaired concentration, ambulation, and eating—compelling non-pharmacologic supports and appetite strategies.

This clarity drives adjuvant-first thinking in neuropathic pain, avoids over-reliance on opioids, and frames the right time to rotate, cross-taper, or escalate.

—

Why Neuropathic Pain Behaves Differently: Physiology and Targets

Central and Peripheral Mechanisms

Neuropathic pain arises when injured or dysregulated nerves amplify and misfire signals. In the spinal cord, repetitive nociceptive input and inflammatory mediators heighten dorsal horn excitability, increasing NMDA receptor activity and altering descending inhibitory pathways. Serotonin and norepinephrine are central to the brain’s ability to “turn down” pain at the spinal cord.

• Hyperexcitable neurons release excess glutamate; NMDA activation drives “wind-up.”
• Inhibitory deficits in GABA and glycine increase signal amplification.
• Microglial activation contributes to the production of cytokines that perpetuate central sensitization.

This is why adjuvant analgesics are indispensable. Antiepileptics calm hyperexcitable neurons; SNRIs/TCAs bolster descending inhibition and stabilize membranes (Hao & Xu, 2018).

—

Adjuvant Analgesics: Antiepileptics and Antidepressants

Antiepileptics

• Gabapentin/Pregabalin: Bind the ?2? subunit of voltage-gated calcium channels, reducing neurotransmitter release and neural hyperexcitability. In our case, gabapentin was ineffective and caused edema; pregabalin was trialed at 25 mg TID with cautious monitoring for dizziness, confusion, and tremors.

Antidepressants

• SNRIs (Duloxetine, Venlafaxine): Elevate serotonin and norepinephrine at descending pathways, reducing spinal signal gain; duloxetine often shines in neuropathic and musculoskeletal pain (Hao & Xu, 2018).
• TCAs (Amitriptyline, Nortriptyline): Multimodal—monoamine reuptake inhibition plus sodium channel blockade—stabilizing nerve membranes and dampening ectopic firing. We used low-dose amitriptyline to replace pregabalin when neurotoxicity emerged; later, nortriptyline was increased (e.g., from 10 mg to 25 mg QHS) to improve tolerability and efficacy.

Using adjuvants with scheduling (e.g., acetaminophen 1,000 mg q8h) builds a stable base, avoids crisis cycles, and reduces opioid burden (Finnerup et al., 2015).

—

Opioids: Titration, Rotation, and Morphine Milligram Equivalents

Why Rotate Opioids

As pain escalates or side effects accumulate, opioid rotation can rebalance efficacy and tolerability. Different opioids have distinct receptor binding profiles, metabolites, and lipophilicity. Incomplete cross-tolerance means a patient tolerant to one opioid may respond better to another—start the new opioid at 25–50% less than the equianalgesic dose (Knotkova et al., 2009).

MME as Common Currency

Converting all opioids to Morphine Milligram Equivalents (MME) standardizes potency and guides rotation. Example factors:

• Oral morphine: 1
• Oral oxycodone: 1.5
• Oral hydromorphone: 4
• IV hydromorphone: 20
• Transdermal fentanyl: 25 mcg/hr? 60 mg oral morphine/day

Calculate total daily MME, choose the new opioid, reduce for safety, then set basal doses and PRN (10–15% of total daily dose q3–4h). This protocol prevents overshooting and stabilizes nighttime pain.

Titration Rules of Thumb

• Short-acting opioids: adjust every 1–2 days.
• Long-acting opioids (e.g., SR morphine): adjust more slowly, over several days.
• Highly lipophilic agents (methadone, buprenorphine): outpatients titrate no faster than every 7 days; inpatients may cautiously titrate every 3–4 days, with close monitoring.

We increased long-acting morphine (e.g., MS Contin from 15 mg to 30 mg q12h) with calculated PRN oxycodone and steadily reassessed. The patient’s daily MMEs rose from ~70 to higher totals as needs evolved; later, PCA use climbed dramatically (ultimately >400 MMEs/day), prompting aggressive reassessment and rotation. References highlight the variability and cautions around MME conversions—clinical judgment is paramount (Nielsen et al., 2017).

—

Opioid-Induced Hyperalgesia: Recognizing and Reversing a Hidden Driver

What Is Opioid-Induced Hyperalgesia (OIH)?

OIH is a paradox: opioids worsen pain sensitivity through neurotoxic metabolite accumulation, NMDA receptor activation, central sensitization, and altered descending modulation. Clinical clues include:

• Worsening pain despite dose escalations
• Diffuse pain spread beyond the original site
• Allodynia, myoclonus, restlessness
• Delirium or hallucinations at higher doses (Lee et al., 2011)

Management Strategy

• Reduce the dose—stop chasing diminishing returns.
• Rotate opioids—switch the pharmacologic profile to reset responsiveness.
• Maximize adjuvants and non-pharmacologic care—cover pain while receptors “reset.”

In our patient, poor response to morphine with neurotoxic symptoms suggested OIH. We rotated to hydromorphone via PCA with recalculated basal and bolus dosing. We also identified and removed contributing agents. Pain remained high, guiding the next step: consider methadone and, ultimately, intrathecal therapy (Lee et al., 2011; Wiffen & Derry, 2017).

—

Methadone for Refractory Neuropathic Pain: Why, When, and How

Unique Pharmacology

Methadone is a racemic mixture; one isomer acts as an NMDA receptor antagonist. This makes methadone potent for central sensitization, OIH, and neuropathic pain, restoring balance at the dorsal horn and improving opioid responsiveness at lower doses. It is highly lipophilic with no toxic metabolites, which favors its use in renal/hepatic impairment and reduces the risk of neurotoxicity (Grudinskas & Gelfand, 2022).

Safety and Protocol

• Long half-life (16–80+ hours) means slow accumulation; titrate very slowly.
• QTc monitoring is mandatory; avoid initiation if QTc > 450 ms; recheck at dose changes.
• Dose conversions are nonlinear; high-MME patients require conservative ratios.
• We initiated 5 mg q8h, then increased to 10 mg q8h after 4 days, while cross-tapering PCA hydromorphone (e.g., reducing basal dose by ~33% daily).

Patient selection and education are critical. We ensure adherence, understanding of delayed accumulation, and clear instructions to prevent inadvertent overdose.

—

When to Move Beyond Systemic Therapy: Intrathecal Pain Pumps

Rationale and Physiology

For intractable pain with unacceptable systemic side effects, an intrathecal drug delivery system delivers micro-doses directly into the CSF—the shortest path to dorsal horn receptors. This yields:

• Micro-dosing potency: Milligrams become micrograms with direct spinal access.
• Superior efficacy and reduced systemic adverse effects.
• Dermatomal precision for segmental pain (e.g., T4–T8 thoracic).

Conversion Potency

• Oral morphine 300 mg ? Intrathecal morphine 1 mg
• IV hydromorphone 1 mg? intrathecal hydromorphone 0.04 mg (40 mcg)

We chose intrathecal hydromorphone with a continuous basal rate (e.g., 0.25 mg/hr) and patient-activated bolus (0.04 mg q6h). Hydrophilic vs lipophilic properties shape spread and onset:

• Hydrophilic (morphine): slower onset, broader CSF spread.
• Lipophilic (fentanyl): faster onset, localized effect.

Candidate Selection and Risks

Appropriate for patients failing conventional therapy or intolerant of side effects. Contraindications include elevated intracranial pressure, coagulopathy, and infection. Potential complications: spinal headache, urinary retention, mild itching, and rare catheter issues (kink, displacement, infection). Sudden recurrence of pain after initial success suggests catheter malfunction and warrants immediate evaluation (Smith & Staats, 2020).

---

Movement Medicine: Chiropractic Care- Video

Integrative Chiropractic Care: Neuromodulation, Mechanics, and Recovery

In complex neuropathic pain, the nervous system is often hyperexcitable, and guarding and rib-spine restrictions impair the thoracic cage mechanics. My chiropractic approach complements medical management by modulating sensory input and restoring movement:

• Addressing Somatic Dysfunction: Gentle thoracic and rib mobilization relieves facet joint restriction, reduces paraspinal hypertonicity, and lowers peripheral afferent drive into the dorsal horn, helping to “turn down” nociceptive noise.
• Soft Tissue and Myofascial Release: Reduces trigger points that perpetuate central sensitization; improved tissue glide eases dermatomal discomfort.
• Sensorimotor Neuromodulation: Spinal manipulation and mobilization increase mechanoreceptive input, engaging gate control mechanisms that inhibit nociception and reshape sensorimotor integration (Pickar, 2002; Haavik & Murphy, 2012).
• Breathing and Postural Integration: Diaphragmatic breathing improves thoracic excursion; postural coaching offloads stressed segments and enhances rib cage mechanics—both critical after pleural procedures and chest tube recovery.
• Rehabilitative Exercise: Graded thoracic mobility work, isometric stabilization, and gentle strengthening break the cycle of fear-avoidance, restoring confidence and function.

These manual techniques pair effectively with regenerative PRP applications, which can further address local inflammatory drivers and support the healing environment around sensitized nerves and restricted thoracic structures. From my clinical observations and ongoing work documented at my professional platforms, I emphasize that low-force, patient-specific techniques are essential in frail or highly sensitized states to prevent flares while leveraging neuromodulatory benefits (Dr. Alexander Jimenez clinical notes: chiropracticscientist.com; linkedin.com/in/dralexjimenez).

—

Regenerative PRP Therapy: Enhancing Neuropathic Pain Management

In our integrative model, we incorporate ultrasound-guided platelet-rich plasma (PRP) therapy as a valuable adjunct for patients with neuropathic pain that has inflammatory or tissue-based perpetuating factors—particularly relevant in post-procedural or postherpetic thoracic cases with allodynia and myofascial guarding.

PRP is prepared from the patient’s own blood by concentrating platelets and their rich array of growth factors (PDGF, TGF-?, VEGF, IGF-1, and others). These bioactive molecules modulate the local neuroinflammatory environment, promote angiogenesis, support Schwann cell activity and axon regeneration, and help reduce ectopic firing and peripheral sensitization.

Clinical Applications in This Context

• Targeted perineural, paravertebral, or intercostal-region PRP injections (under ultrasound guidance) can improve nerve gliding, address post-procedural scar tissue or adhesions from chest tube/thoracentesis complications, and calm localized inflammation contributing to dermatomal pain.
• PRP serves as a non-opioid bridge that may lower overall pharmacologic burden while complementing chiropractic neuromodulation—creating a more favorable tissue environment for manual therapy and rehabilitation to take hold.
• Emerging clinical reports and series support PRP for postherpetic neuralgia, intercostal neuralgia, and radicular/neuropathic thoracic pain, with many patients experiencing meaningful pain reduction, improved function, and decreased analgesic needs when used judiciously in multimodal plans.

In this case, ultrasound-guided PRP applications to the thoracic paraspinal and costal regions were integrated at appropriate stages to address residual mechanical and inflammatory contributors alongside pharmacologic optimization and neuromodulation. This regenerative layer aligns with our clinic’s focus on supporting nerve and tissue recovery in complex neuropathic and post-injury pain states.

—

Functional Medicine Layer: Nutrition, Inflammation, and Resilience

The patient’s weight loss, anorexia, and fatigue flag metabolic stress that worsens pain perception. We assess:

• Nutrient status (protein, omega-3s, micronutrients)
• Inflammation (CRP, cytokine milieu)
• Gut health (microbiome, motility)
• Sleep and stress physiology (circadian alignment, autonomic balance)

Targeted nutrition and supplements can reduce systemic inflammatory tone, support tissue repair, and enhance resilience, helping adjuvants, opioids, and regenerative interventions work more predictably while mitigating side effects.

—

Psychosocial and Spiritual Dimensions: Team-Based Support

Severe neuropathic pain provokes moral, spiritual, and social distress. Our licensed clinical social worker and chaplain team facilitates:

• Meaning-making conversations about suffering, legacy, and priorities
• Family dialogues to align expectations, clarify goals, and improve support
• Coping skills to reduce anxiety that amplifies pain perception

Addressing these dimensions stabilizes the nervous system’s stress response, improving pain thresholds and medication responsiveness.

—

Outcomes, Reassessment, and Honoring Goals of Care

Despite escalating MMEs and optimized adjuvants, the patient’s pain remained refractory until intrathecal therapy. With intrathecal hydromorphone delivery, pain reached a tolerable level (~3/10). We tapered IV PCA and carefully cross-tapered methadone. Dexamethasone improved appetite and antiemetic effects; later, olanzapine improved nausea and intake. She was discharged after 45 days with arrangements for a compounded subcutaneous infusion (BAD: Benadryl, Ativan, Dexamethasone) for refractory nausea management in the home setting.

With improved pain control and functional gains, she returned home to continue recovery with family support and ongoing multidisciplinary outpatient care, including chiropractic adjustments, regenerative follow-up, and pump management. Her family expressed gratitude for the regained comfort, improved ability to participate in daily activities, and enhanced quality of life. This journey underscores that successful pain care is not linear; it is dynamic and iterative, and it must remain aligned with the patient’s goals and dignity.

—

Why This Multidisciplinary Approach Works

Complex neuropathic pain demands:

• Physiologic precision (adjuvants, NMDA-aware opioid strategies, cautious titration)
• Structural and regenerative insight (chiropractic correction of rib-spine mechanics, soft tissue relief, and PRP to modulate inflammation and support tissue/nerve repair)
• Systemic balance (nutrition, inflammation control)
• Psychosocial integration (emotional, spiritual support)
• Medical safety (QTc, renal/hepatic considerations, cross-tolerance, catheter vigilance)

Our collaboration at Injury Medical Clinic PA—uniting Internal Medicine oversight by Dr. Maria Guadalupe Cardenas, MD, with Chiropractic, Regenerative Medicine (including PRP), and Functional Medicine—creates a coherent strategy that adapts to changing clinical realities. It is how we meet complex neuropathic pain with clarity, courage, and compassionate science.

—

References

• The ASAM essentials of addiction medicine (3rd ed.) (Fine & Portenoy, 2019). Wolters Kluwer.
• Treatment of neuropathic pain by increasing spinal cord inhibitory neurotransmission (Hao & Xu, 2018). Neuroscience & Biobehavioral Reviews, 89, 161–169.
• Opioid rotation: The science and the limitations of the equianalgesic dose table (Knotkova, Fine, & Portenoy, 2009). Journal of Pain and Symptom Management, 38(3), 426–439.
• A commentary on the challenges of calculating morphine equivalent doses (Nielsen et al., 2017). Drug and Alcohol Dependence, 172, e32–e33.
• Neurophysiological effects of spinal manipulation (Pickar, 2002). The Spine Journal, 2(5), 357–371.
• Opioid dependence and addiction during opioid treatment of chronic pain (Ballantyne & LaForge, 2007). Pain, 129(3), 235–255.
• Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis (Finnerup et al., 2015). The Lancet Neurology, 14(2), 162–173.
• The role of spinal manipulation in addressing disordered sensorimotor integration and altered motor control (Haavik & Murphy, 2012). Journal of Electromyography and Kinesiology, 22(5), 768–776.
• A comprehensive review of opioid-induced hyperalgesia (Lee et al., 2011). Pain Physician, 14(2), 145–161.
• Methadone for Pain Management: A Comprehensive Review (Grudinskas & Gelfand, 2022). Journal of Pain and Palliative Care Pharmacotherapy.
• Intrathecal Drug Delivery for Refractory Pain (Smith & Staats, 2020). Current Pain and Headache Reports.
• Opioid-Induced Hyperalgesia: Pathophysiology and Clinical Implications (Wiffen & Derry, 2017). Cochrane Database of Systematic Reviews.
• Integrative approaches in pain management (Anderson & Miller, 2021). Oxford University Press.
• Emerging evidence on PRP for neuropathic and postherpetic pain (Anitua et al., 2024; El-Hamd et al., 2024; clinical series on intercostal and radicular applications).

—

SEO tags: neuropathic pain, postherpetic neuralgia, thoracic radicular pain, complex regional pain, intercostal neuralgia, post-procedural neuropathic pain, opioid rotation, morphine milligram equivalents, opioid-induced hyperalgesia, methadone NMDA antagonism, intrathecal pain pump, chiropractic neuromodulation, gate control theory, thoracic dermatomal pain, functional medicine inflammation, regenerative medicine, PRP therapy, platelet rich plasma, ultrasound guided PRP injections, perineural PRP, multidisciplinary clinic, internal medicine oversight, El Paso Texas, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Alex Jimenez DC APRN FNP-BC CFMP IFMCP ATN CCST, Dr. Maria Guadalupe Cardenas MD NPI 1164426749 Texas J2933